AI Detection for Cardiovascular Disease Prevention
(AI INFORM Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if AI can identify coronary artery calcifications (CAC) on chest CT scans to help doctors start or adjust treatments that prevent heart problems. The AI tool, Nanox.AI Coronary Artery Calcification Assessment, analyzes CT scans and informs doctors about the presence of CAC, potentially improving preventive care. Participants should have had a chest CT scan in the last three years and should not have a history of heart disease or cancer. As an unphased trial, this study offers participants the chance to contribute to innovative research that could enhance heart disease prevention strategies.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that this AI platform is safe for cardiovascular disease prevention?
Research has shown that the Nanox.AI Coronary Artery Calcification Assessment helps identify heart disease risks by examining chest CT scans. Although the safety of this AI tool hasn't been tested on people like a new drug, it uses existing CT scans and doesn't introduce new physical risks to patients.
Nanox.AI's system has detected heart disease risks in many patients without any reported negative effects from the AI itself. The technology analyzes scan images and provides information to doctors, resulting in no additional side effects from using this software.12345Why are researchers excited about this trial?
Researchers are excited about the AI Detection for Cardiovascular Disease Prevention trial because it uses cutting-edge AI technology to identify coronary artery calcification from chest CT scans. Unlike traditional methods that rely on manual interpretation by radiologists, this AI-based approach promises faster and potentially more accurate detection, helping doctors catch early signs of heart disease sooner. This could lead to timely interventions and personalized treatment plans, ultimately aiming to improve patient outcomes by preventing the progression of cardiovascular disease.
What evidence suggests that this AI platform is effective for detecting coronary artery calcifications?
Studies have shown that the Nanox.AI platform effectively detects calcium buildup in the heart's arteries, an early sign of heart disease. Research indicates that this AI tool identifies moderate to severe levels of this buildup in about 58% of patients. In this trial, one group will receive notification of coronary artery calcification detected by the AI, enabling doctors to start preventive treatments sooner, which may lead to better health outcomes. The other group will not receive notification. The AI technology not only finds these calcium buildups but also measures them, providing a detailed view of heart health risk.13467
Are You a Good Fit for This Trial?
This trial is for individuals aged 40-75 who've had a chest CT scan in the last 3 years and have no history of coronary artery disease, cancer, or any other life-limiting conditions. It's aimed at enhancing cardiovascular disease prevention.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Notification or non-notification of coronary artery calcification detected by AI, followed by recommendation or non-recommendation of preventive therapy
Follow-up
Participants are monitored for changes in LDL-C, initiation or intensification of preventive therapies, and occurrence of cardiovascular events
What Are the Treatments Tested in This Trial?
Interventions
- Nanox.AI Coronary Artery Calcification Assessment
Find a Clinic Near You
Who Is Running the Clinical Trial?
Brigham and Women's Hospital
Lead Sponsor
Nano-X Imaging Limited
Collaborator